Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) Sees Significant Drop in Short Interest

Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) was the recipient of a large drop in short interest in February. As of February 27th, there was short interest totaling 401,483 shares, a drop of 46.5% from the February 12th total of 750,201 shares. Based on an average trading volume of 158,246 shares, the short-interest ratio is presently 2.5 days. Approximately 15.9% of the shares of the stock are short sold. Approximately 15.9% of the shares of the stock are short sold. Based on an average trading volume of 158,246 shares, the short-interest ratio is presently 2.5 days.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on ASBP. Wall Street Zen upgraded Aspire Biopharma to a “sell” rating in a research report on Saturday, January 17th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aspire Biopharma in a research note on Wednesday, January 21st. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has an average rating of “Sell”.

Aspire Biopharma Stock Down 6.7%

Shares of Aspire Biopharma stock traded down $0.08 during trading on Friday, hitting $1.05. 163,125 shares of the stock traded hands, compared to its average volume of 186,757. The stock has a market cap of $2.82 million, a price-to-earnings ratio of -0.05 and a beta of 0.88. Aspire Biopharma has a 52 week low of $1.04 and a 52 week high of $35.01. The firm’s fifty day moving average is $1.92 and its 200-day moving average is $7.82.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. CIBC Bancorp USA Inc. bought a new position in shares of Aspire Biopharma during the third quarter valued at about $28,000. XTX Topco Ltd raised its position in Aspire Biopharma by 853.2% during the 4th quarter. XTX Topco Ltd now owns 265,471 shares of the company’s stock valued at $35,000 after purchasing an additional 237,620 shares during the last quarter. Finally, Jane Street Group LLC raised its position in Aspire Biopharma by 625.8% during the 2nd quarter. Jane Street Group LLC now owns 152,552 shares of the company’s stock valued at $41,000 after purchasing an additional 131,533 shares during the last quarter. 19.17% of the stock is owned by hedge funds and other institutional investors.

About Aspire Biopharma

Aspire Biopharma Inc is a specialty pharmaceutical company dedicated to developing and commercializing inhaled therapeutics for cardiopulmonary emergencies and respiratory diseases. The firm leverages proprietary formulation and drug-delivery technologies to repurpose established active pharmaceutical ingredients, aiming to enhance onset of action and improve patient convenience in acute settings. Aspire’s focus on pulmonary administration differentiates its approach from traditional oral or injectable treatments for asthma, allergic reactions, and other respiratory conditions.

The company’s lead asset is a reformulated metered-dose inhaler version of epinephrine designed to serve as an over-the-counter or prescription rescue therapy for acute bronchospasm and anaphylaxis.